
Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.
A recap of the FDA submissions and regulatory decisions in urology from May 2025.
Welcome to Urology Times’® monthly FDA update! In May, key developments included 2 FDA Advisory Committee meetings on upcoming regulatory decisions, movement of a point-of-care men’s sexual health test into FDA review, and advancement of CAN-2409 along its regulatory pathway for localized prostate cancer.





